Chong Kun Dang Pharmaceutical Corp. : Good timing to anticipate a continuation of the trend
Entry price | Target | Stop-loss | Potential |
---|
₩175,000 |
₩210,000 |
₩155,000 |
+20% |
---|
Shares in Chong Kun Dang Pharmaceutical Corp. show a positive technical chart pattern over the medium term. The timing to jump back on the rising trend seems good.
Summary● The company has strong fundamentals. More than 70% of listed companies have a lower mix of growth, profitability, debt and visibility criteria.
● The company has solid fundamentals for a short-term investment strategy.
Strengths● Historically, the company has been releasing figures that are above expectations.
● Over the past year, analysts have regularly revised upwards their sales forecast for the company.
● For the last week, the earnings per share forecast has been revised upwards. According to recent estimates, analysts give a positive overview of the stock
● For the last few months, EPS revisions have remained quite promising. Analysts now anticipate higher profitability levels than before.
● For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
● The stock is in a well-established, long-term rising trend above the technical support level at 113000 KRW
Weaknesses● Stock prices approach a strong long-term resistance in weekly data at KRW 198500.
● The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
The content herein constitutes a general investment recommendation, prepared in accordance with provisions aimed at preventing market abuse by Surperformance, the publisher of MarketScreener.com. More specifically, this recommendation is based on factual elements and expresses a sincere, complete, and balanced opinion. It relies on internal or external data, considered reliable as of the date of their release. Nevertheless, this information, and the resulting recommendation, may contain inaccuracies, errors, or omissions, for which Surperformance cannot be held responsible. This recommendation, which in no way constitutes investment advice, may not be suitable for all investor profiles. The reader acknowledges and accepts that any investment in a financial instrument involves risks, for which they assume full responsibility, without recourse against Surperformance. Surperformance commits to disclosing any conflict of interest that may affect the objectivity of its recommendations.